newsfilter
← Latest News
GlobeNewswire·

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2